Products billed under this code include Bendamustine, Bendamustine Hydrochloride, Treanda.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Bendamustine | Accord Healthcare Inc | 16729-0250-03 | 25 | $46.15 |
| Bendamustine | Accord Healthcare Inc | 16729-0251-05 | 100 | $184.60 |
| Bendamustine | Eugia US LLC | 55150-0392-01 | 100 | $184.60 |
| Bendamustine | Apotex Corp | 60505-6096-00 | 100 | $184.60 |
| Bendamustine | BluePoint Laboratories | 68001-0572-41 | 100 | $184.60 |
| Bendamustine | Meitheal Pharmaceuticals Inc. | 71288-0102-10 | 25 | $46.15 |
| Bendamustine | Meitheal Pharmaceuticals Inc. | 71288-0103-20 | 100 | $184.60 |
| Bendamustine Hydrochloride | Eugia US LLC | 55150-0391-01 | 25 | $46.15 |
| Bendamustine Hydrochloride | Apotex Corp | 60505-6095-00 | 25 | $46.15 |
| Treanda | Cephalon, LLC | 63459-0390-08 | 25 | $46.15 |
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Treanda | Cephalon, LLC | 63459-0391-20 | 100 | $184.60 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $1.846 | −$1.114 | 1 MG | Inj, bendamustine (nos) 1mg | v1, posted September 17, 2026 |
| 3Q26 | $2.96 | +$0.801 | 1 MG | Inj, bendamustine hcl, 1mg | v1, posted September 15, 2026 |
| 2Q26 | $2.159 | +$0.112 | 1 MG | Inj, bendamustine hcl, 1mg | v1, posted September 15, 2026 |
| 1Q26 | $2.047 | +$0.164 | 1 MG | Inj, bendamustine hcl, 1mg | v1, posted September 15, 2026 |
| 4Q25 | $1.883 | +$0.033 | 1 MG | Inj, bendamustine hcl, 1mg | v1, posted September 8, 2026 |
| 3Q25 | $1.85 | +$0.61 | 1 MG | Inj, bendamustine hcl, 1mg | v1, posted March 10, 2026 |
| 2Q25 | $1.24 | −$0.562 | 1 MG | Inj, bendamustine hcl, 1mg | v1, posted March 10, 2026 |
| 1Q25 | $1.802 | −$1.018 | 1 MG | Inj., treanda 1 mg | v1, posted December 19, 2025 |
| 4Q24 | $2.82 | −$2.544 | 1 MG | Inj., treanda 1 mg | v1, posted June 11, 2025 |
| 3Q24 | $5.364 | −$2.992 | 1 MG | Inj., treanda 1 mg | v1, posted June 11, 2025 |
| 2Q24 | $8.356 | −$0.835 | 1 MG | Inj., treanda 1 mg | v1, posted March 11, 2025 |
| 1Q24 | $9.191 | −$2.224 | 1 MG | Inj., treanda 1 mg | v1, posted December 19, 2024 |
| 4Q23 | $11.415 | −$0.867 | 1 MG | Inj., treanda 1 mg | v1, posted October 10, 2024 |
| 3Q23 | $12.282 | −$2.091 | 1 MG | Inj., treanda 1 mg | v1, posted June 5, 2024 |
| 2Q23 | $14.373 | −$0.449 | 1 MG | Inj., treanda 1 mg | v1, posted February 23, 2024 |
| 1Q23 | $14.822 | −$1.708 | 1 MG | Inj., treanda 1 mg | v1, posted December 6, 2023 |
| 4Q22 | $16.53 | −$1.17 | 1 MG | Inj., treanda 1 mg | v1, posted June 22, 2023 |
| 3Q22 | $17.70 | −$1.674 | 1 MG | Inj., treanda 1 mg | v1, posted June 9, 2023 |
| 2Q22 | $19.374 | −$1.315 | 1 MG | Inj., treanda 1 mg | v1, posted December 14, 2022 |
| 1Q22 | $20.689 | −$1.323 | 1 MG | Inj., treanda 1 mg | v1, posted June 8, 2022 |
| 4Q21 | $22.012 | −$1.785 | 1 MG | Inj., treanda 1 mg | v1, posted June 2, 2022 |
| 3Q21 | $23.797 | −$0.181 | 1 MG | Inj., treanda 1 mg | v1, posted June 2, 2022 |
| 2Q21 | $23.978 | −$0.603 | 1 MG | Inj., treanda 1 mg | v1, posted March 1, 2022 |
| 1Q21 | $24.581 | – | 1 MG | Inj., treanda 1 mg | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.
